These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 26755885)
21. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Noureddin M; Rinella ME Clin Liver Dis; 2015 May; 19(2):361-79. PubMed ID: 25921668 [TBL] [Abstract][Full Text] [Related]
22. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. Streba LA; Vere CC; Rogoveanu I; Streba CT World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859 [TBL] [Abstract][Full Text] [Related]
23. Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. Yoshiji H; Noguchi R; Kaji K; Ikenaka Y; Shirai Y; Namisaki T; Kitade M; Tsujimoto T; Kawaratani H; Fukui H J Gastroenterol; 2010 Apr; 45(4):443-50. PubMed ID: 19941011 [TBL] [Abstract][Full Text] [Related]
24. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. Reeves HL; Zaki MY; Day CP Dig Dis Sci; 2016 May; 61(5):1234-45. PubMed ID: 26921078 [TBL] [Abstract][Full Text] [Related]
25. Hepatocellular Carcinoma Chemoprevention with Generic Agents. Rasha F; Paul S; Simon TG; Hoshida Y Semin Liver Dis; 2022 Nov; 42(4):501-513. PubMed ID: 36104114 [TBL] [Abstract][Full Text] [Related]
26. Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention. Lange NF; Radu P; Dufour JF J Hepatol; 2021 Nov; 75(5):1217-1227. PubMed ID: 34339764 [TBL] [Abstract][Full Text] [Related]
28. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. Baffy G; Brunt EM; Caldwell SH J Hepatol; 2012 Jun; 56(6):1384-91. PubMed ID: 22326465 [TBL] [Abstract][Full Text] [Related]
29. Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance. Yoshiji H; Noguchi R; Namisaki T; Moriya K; Kitade M; Aihara Y; Douhara A; Yamao J; Fujimoto M; Toyohara M; Mitoro A; Sawai M; Yoshida M; Morioka C; Uejima M; Uemura M; Fukui H Oncol Rep; 2013 Aug; 30(2):545-52. PubMed ID: 23708326 [TBL] [Abstract][Full Text] [Related]
30. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. Takami T; Yamasaki T; Saeki I; Matsumoto T; Suehiro Y; Sakaida I World J Gastroenterol; 2016 Aug; 22(32):7252-63. PubMed ID: 27621572 [TBL] [Abstract][Full Text] [Related]
31. Causes of and prevention strategies for hepatocellular carcinoma. Cabibbo G; Maida M; Genco C; Antonucci M; Cammà C Semin Oncol; 2012 Aug; 39(4):374-83. PubMed ID: 22846856 [TBL] [Abstract][Full Text] [Related]
32. Acyclic retinoid in the chemoprevention of hepatocellular carcinoma (review). Kojima S; Okuno M; Matsushima-Nishiwaki R; Friedman SL; Moriwaki H Int J Oncol; 2004 Apr; 24(4):797-805. PubMed ID: 15010815 [TBL] [Abstract][Full Text] [Related]
33. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Marengo A; Rosso C; Bugianesi E Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416 [TBL] [Abstract][Full Text] [Related]
34. Suppression of FGF signaling: a putative mechanism for the chemopreventive effects of acyclic retinoid in hepatocellular carcinoma. Wang L; Levin MS Gastroenterology; 2005 Jan; 128(1):228-31. PubMed ID: 15633140 [No Abstract] [Full Text] [Related]
35. Chemopreventive and therapeutic potential of tea polyphenols in hepatocellular cancer. Darvesh AS; Bishayee A Nutr Cancer; 2013; 65(3):329-44. PubMed ID: 23530632 [TBL] [Abstract][Full Text] [Related]
36. Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. Okuno M; Kojima S; Moriwaki H J Gastroenterol Hepatol; 2001 Dec; 16(12):1329-35. PubMed ID: 11851828 [TBL] [Abstract][Full Text] [Related]
37. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Chettouh H; Lequoy M; Fartoux L; Vigouroux C; Desbois-Mouthon C Liver Int; 2015 Oct; 35(10):2203-17. PubMed ID: 26123841 [TBL] [Abstract][Full Text] [Related]
38. Development and prognosis of hepatocellular carcinoma in patients with diabetes. Nakatsuka T; Tateishi R Clin Mol Hepatol; 2023 Jan; 29(1):51-64. PubMed ID: 35903020 [TBL] [Abstract][Full Text] [Related]
39. Why should the gastroenterologist bother about obesity? An oncologic point of view. Charette N; Leclercq IA Acta Gastroenterol Belg; 2010; 73(4):504-9. PubMed ID: 21299162 [TBL] [Abstract][Full Text] [Related]
40. The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives. Facciorusso A Curr Diabetes Rev; 2013 Sep; 9(5):382-6. PubMed ID: 23845075 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]